Gemini Therapeutics (GMTX) Competitors $57.74 +0.83 (+1.46%) As of 07/14/2025 Add Compare Share Share Competitors Stock AnalysisChartCompetitorsFinancialsInsider TradesSEC FilingsTrendsBuy This Stock GMTX vs. BBIO, BPMC, VRNA, ROIV, ELAN, RVMD, LEGN, GRFS, TGTX, and NUVLShould you be buying Gemini Therapeutics stock or one of its competitors? The main competitors of Gemini Therapeutics include BridgeBio Pharma (BBIO), Blueprint Medicines (BPMC), Verona Pharma PLC American Depositary Share (VRNA), Roivant Sciences (ROIV), Elanco Animal Health (ELAN), Revolution Medicines (RVMD), Legend Biotech (LEGN), Grifols (GRFS), TG Therapeutics (TGTX), and Nuvalent (NUVL). These companies are all part of the "pharmaceutical products" industry. Gemini Therapeutics vs. Its Competitors BridgeBio Pharma Blueprint Medicines Verona Pharma PLC American Depositary Share Roivant Sciences Elanco Animal Health Revolution Medicines Legend Biotech Grifols TG Therapeutics Nuvalent Gemini Therapeutics (NASDAQ:GMTX) and BridgeBio Pharma (NASDAQ:BBIO) are both mid-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their institutional ownership, earnings, media sentiment, valuation, profitability, dividends, risk and analyst recommendations. Is GMTX or BBIO more profitable? Gemini Therapeutics has a net margin of 0.00% compared to BridgeBio Pharma's net margin of -524.25%. BridgeBio Pharma's return on equity of 0.00% beat Gemini Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Gemini TherapeuticsN/A -38.78% -35.88% BridgeBio Pharma -524.25%N/A -94.43% Do insiders & institutionals have more ownership in GMTX or BBIO? 75.4% of Gemini Therapeutics shares are held by institutional investors. Comparatively, 99.9% of BridgeBio Pharma shares are held by institutional investors. 12.9% of Gemini Therapeutics shares are held by company insiders. Comparatively, 18.2% of BridgeBio Pharma shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term. Which has stronger earnings & valuation, GMTX or BBIO? Gemini Therapeutics has higher earnings, but lower revenue than BridgeBio Pharma. Gemini Therapeutics is trading at a lower price-to-earnings ratio than BridgeBio Pharma, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioGemini TherapeuticsN/AN/A-$71.87M-$1.00-57.74BridgeBio Pharma$221.90M40.27-$535.76M-$3.53-13.33 Do analysts prefer GMTX or BBIO? BridgeBio Pharma has a consensus price target of $61.20, indicating a potential upside of 30.04%. Given BridgeBio Pharma's stronger consensus rating and higher possible upside, analysts plainly believe BridgeBio Pharma is more favorable than Gemini Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Gemini Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00BridgeBio Pharma 0 Sell rating(s) 0 Hold rating(s) 15 Buy rating(s) 0 Strong Buy rating(s) 3.00 Does the media prefer GMTX or BBIO? In the previous week, BridgeBio Pharma had 20 more articles in the media than Gemini Therapeutics. MarketBeat recorded 21 mentions for BridgeBio Pharma and 1 mentions for Gemini Therapeutics. BridgeBio Pharma's average media sentiment score of 0.82 beat Gemini Therapeutics' score of 0.00 indicating that BridgeBio Pharma is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Gemini Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral BridgeBio Pharma 7 Very Positive mention(s) 3 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Which has more risk and volatility, GMTX or BBIO? Gemini Therapeutics has a beta of -0.12, meaning that its share price is 112% less volatile than the S&P 500. Comparatively, BridgeBio Pharma has a beta of 1.15, meaning that its share price is 15% more volatile than the S&P 500. SummaryBridgeBio Pharma beats Gemini Therapeutics on 11 of the 15 factors compared between the two stocks. Get Gemini Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for GMTX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding GMTX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart GMTX vs. The Competition Export to ExcelMetricGemini TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$2.50B$753.14M$5.56B$9.30BDividend YieldN/A4.84%4.23%4.03%P/E Ratio-57.741.4328.6119.64Price / SalesN/A25.50437.49188.30Price / CashN/A19.5636.0257.93Price / Book19.986.698.185.63Net Income-$71.87M-$4.53M$3.23B$257.73M7 Day Performance9.01%1.95%-0.25%0.07%1 Month Performance7.50%1.86%5.40%8.32%1 Year Performance17.29%7.71%26.35%13.78% Gemini Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)GMTXGemini TherapeuticsN/A$57.74+1.5%N/A+22.4%$2.50BN/A-57.7430News CoverageBBIOBridgeBio Pharma4.631 of 5 stars$43.50-1.1%$58.85+35.3%+68.7%$8.35B$221.90M-12.32400Analyst ForecastAnalyst RevisionBPMCBlueprint Medicines1.0895 of 5 stars$128.40+0.0%$128.25-0.1%+8.2%$8.29B$508.82M-51.98640Positive NewsVRNAVerona Pharma PLC American Depositary Share2.2695 of 5 stars$91.20-0.4%$107.36+17.7%+387.3%$7.79B$42.28M-45.6030Analyst ForecastROIVRoivant Sciences2.7955 of 5 stars$10.74-2.3%$17.50+62.9%-1.2%$7.47B$29.05M-42.96860Positive NewsELANElanco Animal Health1.4909 of 5 stars$14.48-1.1%$15.33+5.9%+9.4%$7.27B$4.44B19.579,000RVMDRevolution Medicines4.5999 of 5 stars$36.67-3.2%$68.00+85.4%-17.8%$7.05B$11.58M-9.17250Analyst ForecastLEGNLegend Biotech3.3699 of 5 stars$35.87+0.6%$72.60+102.4%-26.7%$6.55B$627.24M-60.802,609GRFSGrifols3.5191 of 5 stars$8.87-2.3%$10.30+16.1%+19.7%$6.24B$7.81B7.5823,822News CoverageGap UpTGTXTG Therapeutics3.6141 of 5 stars$35.98-2.0%$40.80+13.4%+78.5%$5.83B$329M149.92290Positive NewsNUVLNuvalent3.302 of 5 stars$77.93-3.2%$119.60+53.5%+1.8%$5.78BN/A-17.7540 Related Companies and Tools Related Companies BridgeBio Pharma Alternatives Blueprint Medicines Alternatives Verona Pharma PLC American Depositary Share Alternatives Roivant Sciences Alternatives Elanco Animal Health Alternatives Revolution Medicines Alternatives Legend Biotech Alternatives Grifols Alternatives TG Therapeutics Alternatives Nuvalent Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:GMTX) was last updated on 7/16/2025 by MarketBeat.com Staff From Our PartnersMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredRevolutionary AI Tech Targets Early Diabetic Blindness Detection FDA Trial UnderwayTiny Stock, Massive Potential— this company’s AI platform is a game changer for healthcare!Interactive Offers | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | Sponsored3..2..1.. AI 2.0 ignition (don’t sleep on this)I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredCentral Banks Are Hoarding Gold – Should You?The AI boom isn’t just transforming technology—it’s redefining global power, increasing government debt, and u...Lear Capital | SponsoredSpecial gold investment soars 2,300% ... 5,090% ... 9,850%In my 54 years as an investor, I’ve seen my share of gold bull markets. But nothing comes close to the rall...Weiss Ratings | SponsoredAll New Social Security Numbers coming July 23?To All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | Sponsored"Death Spiral" Threatening Your SavingsThe "Death Spiral" Threatening Your Savings But this time, it's not just Dalio ringing the alarm bells…GoldCo Precious Metals | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Gemini Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Gemini Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free GMTX Stock Alerts